Go Pro

Myriad Genetics (MYGN) 10K Form and Latest SEC Filings 2026

Myriad Genetics logo
$3.42 +0.06 (+1.79%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$3.42 0.00 (-0.15%)
As of 09/11/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Myriad Genetics SEC Filings & Recent Activity

Myriad Genetics (NASDAQ:MYGN) has submitted 562+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Myriad Genetics's financial statements. The most recent filing was a Form 4 submitted on September 8, 2026.

Form 4
MYRIAD GENETICS INC Reports Ownership Change on Sep. 8, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

10-Q
Myriad Genetics Files Quarterly Report on Jul. 31, 2026

The 10-Q contains Myriad Genetics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Myriad Genetics SEC Filing History

Browse Myriad Genetics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
09/08/2026 3:18 PM
Fox Jennifer Lynne (1914879) Reporting
Myriad Genetics (899923) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/04/2026 11:57 AM
BlackRock Portfolio Management LLC (2052113) Filed by
Myriad Genetics (899923) Subject
Form SCHEDULE 13G
08/14/2026 3:59 PM
GLENVIEW CAPITAL MANAGEMENT, LLC (1138995) Filed by
Myriad Genetics (899923) Subject
Form SCHEDULE 13G/A
08/07/2026 9:09 AM
Myriad Genetics (899923) Subject
STATE STREET CORP (93751) Filed by
STATE STREET CORP (93751) Filed by
Form SCHEDULE 13G
07/31/2026 7:01 AM
Myriad Genetics (899923) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
06/23/2026 7:32 AM
Myriad Genetics (899923) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/12/2026 5:05 PM
Donnelly Brian J (2065630) Reporting
Myriad Genetics (899923) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/12/2026 5:06 PM
Myriad Genetics (899923) Issuer
Raha Samraat S. (1738340) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2026 3:20 PM
Kumar Rashmi (1824720) Reporting
Myriad Genetics (899923) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/08/2026 10:17 AM
Kumar Rashmi (1824720) Reporting
Myriad Genetics (899923) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/04/2026 3:05 PM
Myriad Genetics (899923) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
06/02/2026 3:20 PM
Jampa Raj (2134322) Reporting
Myriad Genetics (899923) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 4:16 PM
Bisaro Paul (1237253) Reporting
Myriad Genetics (899923) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 10:38 AM
Myriad Genetics (899923) Subject
STATE STREET CORP (93751) Filed by
STATE STREET CORP (93751) Filed by
Form SCHEDULE 13G
05/06/2026 5:05 AM
Myriad Genetics (899923) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/04/2026 3:35 PM
Donnelly Brian J (2065630) Reporting
Myriad Genetics (899923) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 3:20 PM
Muzzey Dale (1922964) Reporting
Myriad Genetics (899923) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 3:20 PM
Myriad Genetics (899923) Issuer
Verratti Mark (1517026) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/14/2026 4:01 PM
Myriad Genetics (899923) Filer
Form DEF 14A
04/14/2026 4:02 PM
Myriad Genetics (899923) Filer
Form DEFA14A
04/14/2026 4:06 PM
Myriad Genetics (899923) Filer
Form ARS
04/07/2026 11:39 AM
BlackRock, Inc. (2012383) Filed by
Myriad Genetics (899923) Subject
Form SCHEDULE 13G/A
03/27/2026 9:49 AM
Myriad Genetics (899923) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/23/2026 3:22 PM
Myriad Genetics (899923) Issuer
Wheeler Benjamin Richard (2082246) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/23/2026 3:22 PM
Myriad Genetics (899923) Issuer
Verratti Mark (1517026) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/23/2026 3:23 PM
Muzzey Dale (1922964) Reporting
Myriad Genetics (899923) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/16/2026 4:58 PM
Haas Kevin Richard (1843872) Reporting
Myriad Genetics (899923) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/16/2026 4:05 PM
Myriad Genetics (899923) Issuer
Raha Samraat S. (1738340) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/16/2026 4:05 PM
Myriad Genetics (899923) Issuer
Wheeler Benjamin Richard (2082246) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/16/2026 4:05 PM
Myriad Genetics (899923) Issuer
Verratti Mark (1517026) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/16/2026 4:05 PM
Donnelly Brian J (2065630) Reporting
Myriad Genetics (899923) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/16/2026 4:05 PM
Fox Jennifer Lynne (1914879) Reporting
Myriad Genetics (899923) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/16/2026 4:06 PM
Muzzey Dale (1922964) Reporting
Myriad Genetics (899923) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/16/2026 4:06 PM
Myriad Genetics (899923) Issuer
Solaiman Shereen (1472827) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/09/2026 6:03 PM
Myriad Genetics (899923) Issuer
Raha Samraat S. (1738340) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2026 11:15 PM
Myriad Genetics (899923) Filer
Form EFFECT
03/04/2026 4:24 PM
Myriad Genetics (899923) Filer
Form 424B3
03/02/2026 3:18 PM
Myriad Genetics (899923) Issuer
Solaiman Shereen (1472827) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 3:10 PM
Myriad Genetics (899923) Filer
Form S-3
Registration statement under Securities Act of 1933  
02/23/2026 3:07 PM
Myriad Genetics (899923) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/11/2026 4:20 PM
INTEGRATED CORE STRATEGIES (0) US
Myriad Genetics (899923) Subject
Form SCHEDULE 13G/A
Shocking AI prediction from the “Billionaire Whisperer" (Ad)

Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percent run, and Nvidia before it climbed more than 50,000 percent. Now Chaikin says a new AI data center technology using 99 percent less electricity, water, and space could accelerate scientific breakthroughs 360-fold, and one company behind it just flashed bullish in his system. See the full research and the ticker Chaikin is watching before this presentation goes offline.tc pixel

Watch Chaikin's free presentation and see the ticker now
02/09/2026 6:54 AM
Myriad Genetics (899923) Subject
STATE STREET CORP (93751) Filed by
STATE STREET CORP (93751) Filed by
Form SCHEDULE 13G
02/03/2026 4:29 PM
Haas Kevin Richard (1843872) Reporting
Myriad Genetics (899923) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/03/2026 4:30 PM
Muzzey Dale (1922964) Reporting
Myriad Genetics (899923) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/03/2026 4:30 PM
Myriad Genetics (899923) Issuer
Verratti Mark (1517026) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/03/2026 4:30 PM
Myriad Genetics (899923) Issuer
Wheeler Benjamin Richard (2082246) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/13/2026 3:39 PM
GLENVIEW CAPITAL MANAGEMENT, LLC (1138995) Filed by
Myriad Genetics (899923) Subject
Form SCHEDULE 13G
01/12/2026 7:31 AM
Myriad Genetics (899923) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/02/2026 3:17 PM
Muzzey Dale (1922964) Reporting
Myriad Genetics (899923) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2025 3:30 PM
Myriad Genetics (899923) Issuer
Wheeler Benjamin Richard (2082246) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2025 3:47 PM
Myriad Genetics (899923) Issuer
Raha Samraat S. (1738340) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2025 3:10 PM
INTEGRATED CORE STRATEGIES (0) US
Myriad Genetics (899923) Subject
Form SCHEDULE 13G/A
11/04/2025 3:32 PM
Ancona Margaret (1843568) Reporting
Myriad Genetics (899923) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/04/2025 5:18 AM
Myriad Genetics (899923) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/03/2025 7:42 PM
Myriad Genetics (899923) Filer
Form 8-K/A
10/31/2025 10:05 AM
Myriad Genetics (899923) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
10/24/2025 3:16 PM
Munk Natalie (1932320) Reporting
Myriad Genetics (899923) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/07/2025 3:02 PM
Myriad Genetics (899923) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/03/2025 3:27 PM
Myriad Genetics (899923) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/22/2025 3:14 PM
Ancona Margaret (1843568) Reporting
Myriad Genetics (899923) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/22/2025 3:14 PM
Myriad Genetics (899923) Issuer
Wheeler Benjamin Richard (2082246) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/22/2025 3:15 PM
Munk Natalie (1932320) Reporting
Myriad Genetics (899923) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/22/2025 3:16 PM
Myriad Genetics (899923) Issuer
Verratti Mark (1517026) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

Myriad Genetics SEC Filings - Frequently Asked Questions

Myriad Genetics (MYGN) has submitted 562+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Myriad Genetics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Myriad Genetics's financial statements page.

The most recent filing was a Form 4 submitted on September 8, 2026. This was an insider ownership change filed by 4 - MYRIAD GENETICS INC (0000899923) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:MYGN are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 9/8/2026. New filings are added as they're published.
From Our Partners